A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 388 participants.

Also called NCT05478252

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 388 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05478252
  • EudraCT 2021-001501-69
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Poland, Slovakia, South Africa (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05478252. Randomized; triple masking; primary purpose treatment. Start 2022-08-03 (actual); primary completion 2023-08-09 (actual). Results posted on 2024-10-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Semaglutide J
Intervention (Drug)
Semaglutide B
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct05478252
Content hash
900474fb6035993f578f57714ffe514d3224ad2ed09cdbc552f491fb95982a37